Does the media favor RNAC or ALVO?

In the previous week, Alvotech had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 3 mentions for Cartesian Therapeutics. Alvotech's average media sentiment score of 0.90 beat Cartesian Therapeutics' score of -0.65 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Alvotech 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or RNAC?

In the previous week, Cartesian Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.37 beat Cartesian Therapeutics' score of -0.65 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer WVE or RNAC?

In the previous week, Cartesian Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.14 beat Cartesian Therapeutics' score of -0.65 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to JBIO or RNAC?

In the previous week, Cartesian Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.91 beat Cartesian Therapeutics' score of -0.65 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Cartesian Therapeutics (RNAC) Competitors

$10.59 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$10.71 +0.12 (+1.10%)

As of 07/2/2026 07:51 PM Eastern

Compare

RNAC vs. CGEM, ALVO, BIOA, WVE, and JBIO

Should you buy Cartesian Therapeutics stock or one of its competitors? MarketBeat compares Cartesian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cartesian Therapeutics include Cullinan Therapeutics (CGEM), Alvotech (ALVO), BioAge Labs (BIOA), WAVE Life Sciences (WVE), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Cullinan Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 81.51%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 207.84%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cartesian Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Cartesian Therapeutics	$2.80M	111.12	-$130.30M	-$5.90	N/A

In the previous week, Cartesian Therapeutics had 3 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 0 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.65 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Cartesian Therapeutics	Negative

Summary

Cartesian Therapeutics beats Cullinan Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Alvotech?

Cartesian Therapeutics (NASDAQ:RNAC) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Alvotech had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 3 mentions for Cartesian Therapeutics. Alvotech's average media sentiment score of 0.90 beat Cartesian Therapeutics' score of -0.65 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Alvotech	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has a net margin of -14.36% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Alvotech	-14.36%	-11.92%	-7.59%

Cartesian Therapeutics presently has a consensus price target of $32.60, suggesting a potential upside of 207.84%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 110.53%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cartesian Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alvotech has higher revenue and earnings than Cartesian Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	111.12	-$130.30M	-$5.90	N/A
Alvotech	$588.90M	1.85	$27.92M	-$0.25	N/A

Summary

Cartesian Therapeutics beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

BioAge Labs has higher revenue and earnings than Cartesian Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	108.16	-$80.61M	-$2.40	N/A
Cartesian Therapeutics	$2.80M	111.12	-$130.30M	-$5.90	N/A

In the previous week, Cartesian Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.37 beat Cartesian Therapeutics' score of -0.65 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

BioAge Labs has a net margin of -871.75% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

BioAge Labs currently has a consensus price target of $43.50, indicating a potential upside of 73.31%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 207.84%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioAge Labs has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

BioAge Labs beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

WAVE Life Sciences presently has a consensus target price of $26.41, indicating a potential upside of 321.91%. Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 207.84%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

In the previous week, Cartesian Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.14 beat Cartesian Therapeutics' score of -0.65 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

WAVE Life Sciences has a net margin of -255.70% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Cartesian Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$71.80M	16.78	-$204.38M	-$1.06	N/A
Cartesian Therapeutics	$2.80M	111.12	-$130.30M	-$5.90	N/A

Summary

WAVE Life Sciences and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Cartesian Therapeutics had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.91 beat Cartesian Therapeutics' score of -0.65 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Jade Biosciences presently has a consensus price target of $47.13, indicating a potential upside of 119.08%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 207.84%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Jade Biosciences has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jade Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics. Jade Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Cartesian Therapeutics	$2.80M	111.12	-$130.30M	-$5.90	N/A

Jade Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Summary

Jade Biosciences and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$311.16M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-1.79	21.61	28.02	24.70
Price / Sales	111.12	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-2.18	8.66	10.96	6.46
Net Income	-$130.30M	$23.81M	$3.57B	$337.01M
7 Day Performance	12.42%	3.39%	2.12%	1.69%
1 Month Performance	81.34%	10.81%	5.25%	3.81%
1 Year Performance	-5.23%	62.61%	33.29%	23.90%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	3.8319 of 5 stars	$10.59 flat	$32.60 +207.8%	-5.2%	$311.16M	$2.80M	N/A	64	News Coverage Analyst Downgrade
CGEM Cullinan Therapeutics	2.2666 of 5 stars	$18.21 -1.1%	$32.00 +75.7%	+125.7%	$1.13B	N/A	N/A	30
ALVO Alvotech	3.2788 of 5 stars	$3.69 -0.8%	$7.60 +106.0%	-60.7%	$1.12B	$588.90M	N/A	1,460	Positive News
BIOA BioAge Labs	2.8727 of 5 stars	$24.55 -1.6%	$43.50 +77.2%	+486.4%	$1.11B	$8.99M	N/A	N/A
WVE WAVE Life Sciences	3.428 of 5 stars	$5.81 +2.3%	$26.41 +354.6%	-10.2%	$1.09B	$42.73M	N/A	240	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. CGEM, ALVO, BIOA, WVE, and JBIO

How does Cartesian Therapeutics compare to Cullinan Therapeutics?

Summary

How does Cartesian Therapeutics compare to Alvotech?

Summary

How does Cartesian Therapeutics compare to BioAge Labs?

Summary

How does Cartesian Therapeutics compare to WAVE Life Sciences?

Summary

How does Cartesian Therapeutics compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. CGEM, ALVO, BIOA, WVE, and JBIO

How does Cartesian Therapeutics compare to Cullinan Therapeutics?

Is CGEM or RNAC more profitable?

Which has more risk and volatility, CGEM or RNAC?

Do institutionals & insiders have more ownership in CGEM or RNAC?

Do analysts prefer CGEM or RNAC?

Which has higher earnings & valuation, CGEM or RNAC?

Does the media refer more to CGEM or RNAC?

Summary

How does Cartesian Therapeutics compare to Alvotech?

Does the media favor RNAC or ALVO?

Is RNAC or ALVO more profitable?

Do analysts prefer RNAC or ALVO?

Which has more volatility & risk, RNAC or ALVO?

Do insiders and institutionals have more ownership in RNAC or ALVO?

Which has preferable earnings and valuation, RNAC or ALVO?

Summary

How does Cartesian Therapeutics compare to BioAge Labs?

Which has better earnings & valuation, BIOA or RNAC?

Does the media prefer BIOA or RNAC?

Is BIOA or RNAC more profitable?

Do analysts recommend BIOA or RNAC?

Do insiders & institutionals believe in BIOA or RNAC?

Which has more volatility & risk, BIOA or RNAC?

Summary

How does Cartesian Therapeutics compare to WAVE Life Sciences?

Do analysts recommend WVE or RNAC?

Do institutionals and insiders believe in WVE or RNAC?

Which has more volatility & risk, WVE or RNAC?

Does the media prefer WVE or RNAC?

Is WVE or RNAC more profitable?

Which has better valuation and earnings, WVE or RNAC?

Summary

How does Cartesian Therapeutics compare to Jade Biosciences?

Does the media refer more to JBIO or RNAC?

Do analysts recommend JBIO or RNAC?

Which has more risk & volatility, JBIO or RNAC?

Do insiders & institutionals believe in JBIO or RNAC?

Which has better earnings and valuation, JBIO or RNAC?

Is JBIO or RNAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools